---
title: "Technical Specification: Transfection Reagents"
description: "Technical specifications for Solarbio transfection reagents — lipid-based DNA/siRNA delivery systems optimized for mammalian cell lines. Transfection efficiency data across cell types, cytotoxicity profiles, mechanism of action, protocol optimization guidelines, and troubleshooting."
---

<script type="application/ld+json">
{
 "@context": "https://schema.org",
 "@type": "TechArticle",
 "headline": "Technical Specification: Transfection Reagents",
 "description": "Technical specifications for Solarbio transfection reagents — lipid-based DNA/siRNA delivery systems optimized for mammalian cell lines. Transfection efficiency data across cell types, cytotoxicity profiles, mechanism of action, protocol optimization guidelines, and troubleshooting.",
 "author": {"@type": "Organization", "name": "Beijing Solarbio Science & Technology Co., Ltd.", "url": "https://solarbio.store"},
 "publisher": {"@type": "Organization", "name": "Solarbio", "url": "https://solarbio.store"}
}
</script>



# Technical Specification: Transfection Reagents

## 1. Product Range

Solarbio offers two transfection reagent formulations designed for different cell type requirements. Solarfect (T2100) is a multi-component lipid formulation optimized for established cell lines. Liposomal Transfection Reagent (T2200) uses an advanced liposome formulation for primary cells and difficult-to-transfect types.

| Product | SKU | Cargo Type | Cell Types | Format |
|---|---|---|---|---|
| Solarfect Transfection Reagent | T2100 | Plasmid DNA, siRNA | HEK293, HeLa, CHO, HepG2, A549, NIH/3T3 | 1 mL, 2 mL |
| Liposomal Transfection Reagent | T2200 | Plasmid DNA, siRNA | Primary cells, stem cells, difficult-to-transfect (HUVEC, MSC, neurons) | 1 mL, 2 mL |

## 2. Technical Parameters

### 2.1 Solarfect (T2100)

| Parameter | Specification |
|---|---|
| Transfection efficiency (HEK293, 24 h) | >80% (GFP reporter, flow cytometry) |
| Cytotoxicity (HEK293 at recommended dose) | <10% (MTT assay, 48 h) |
| siRNA knockdown efficiency | >70% (48 h, 20 nM siRNA, qPCR readout) |
| DNA amount (24-well) | 0.5–1 μg per well |
| siRNA amount (24-well) | 10–100 pmol per well |
| Reagent-to-DNA ratio (v/w) | 2–3:1 (μL reagent : μg DNA) |
| Optimal cell confluency at transfection | 70–90% |
| Serum compatibility | Works in serum-containing medium (no change needed) |
| Antibiotic compatibility | Avoid during transfection (penicillin/streptomycin) |
| Storage | 2–8°C, 12 months |
| Complex formation time | 15–20 min at RT |

### 2.2 Liposomal Transfection Reagent (T2200)

| Parameter | Specification |
|---|---|
| Transfection efficiency (HUVEC, 48 h) | >60% (GFP reporter) |
| Transfection efficiency (MSC, 72 h) | >40% (GFP reporter) |
| Cytotoxicity (HUVEC at recommended dose) | <15% (MTT assay) |
| siRNA knockdown efficiency (primary cells) | >60% (48–72 h, 50 nM siRNA) |
| DNA amount (24-well) | 0.5–1 μg per well |
| Reagent-to-DNA ratio (v/w) | 3–4:1 (μL reagent : μg DNA) |
| Optimal cell confluency | 60–80% |
| Serum compatibility | Reduced serum (Opti-MEM or serum-free) for complex formation |
| Storage | 2–8°C, 12 months |
| Complex formation time | 15–30 min at RT |

## 3. Mechanism of Action

Lipid-based transfection reagents consist of cationic lipids (e.g., DOTMA, DOTAP) and neutral co-lipids (typically DOPE) formulated into liposomes. The transfection mechanism proceeds through five distinct steps:

**Step 1 — Complex formation:** Cationic liposomes interact electrostatically with negatively charged nucleic acids (DNA or siRNA) to form lipoplexes. The net positive charge of the complex facilitates interaction with the negatively charged cell surface.

```
Cationic liposome (+ charge)  +  DNA/siRNA (- charge)  →  Lipoplex (net + charge)
```

**Step 2 — Cellular uptake:** Lipoplexes bind to the anionic cell surface proteoglycans (heparan sulfate) and are internalized primarily via clathrin-mediated endocytosis, with minor contributions from caveolin-mediated uptake and macropinocytosis.

**Step 3 — Endosomal escape:** The key limiting step. The fusogenic lipid DOPE undergoes a lamellar-to-hexagonal phase transition at acidic pH in the endosome, destabilizing the endosomal membrane and releasing nucleic acid into the cytoplasm. Approximately 1–5% of internalized nucleic acid escapes the endosome.

**Step 4 — Intracellular trafficking:** Plasmid DNA must traverse the cytoplasm and enter the nucleus. Nuclear entry occurs during mitosis when the nuclear envelope breaks down. siRNA remains in the cytoplasm for RISC loading.

**Step 5 — Expression/silencing:** Plasmid DNA transcription produces mRNA, followed by translation. siRNA is loaded into the RNA-induced silencing complex (RISC), guiding sequence-specific mRNA cleavage.

## 4. Protocol Overview — Plasmid DNA Transfection (24-well Plate)

| Step | Detail | Time |
|---|---|---|
| Seed cells | 5×10⁴ cells/well in 500 μL complete medium | Day 1 |
| Culture | Grow to 70–90% confluency | 24 h |
| DNA dilution | 0.5–1 μg DNA in 50 μL Opti-MEM or PBS | Day 2 |
| Reagent dilution | 1.5–3 μL reagent in 50 μL Opti-MEM | Day 2 |
| Complex formation | Mix diluted DNA + reagent; pipette gently | 15–20 min at RT |
| Add to cells | Add 100 μL complexes directly to cells; swirl gently | — |
| Medium change | Optional (if serum-free complexes); change after 4–6 h | — |
| Readout | GFP/mCherry: 24–48 h; Luciferase: 24–72 h | Day 3–4 |

## 5. Transfection Efficiency by Cell Type

| Cell Line | Reagent | Optimal Ratio (μL:μg) | Efficiency (%) | Viability (%) |
|---|---|---|---|---|
| HEK293 | T2100 | 2:1 | 85–92 | >95 |
| HeLa | T2100 | 3:1 | 75–85 | >90 |
| CHO-K1 | T2100 | 2:1 | 70–80 | >90 |
| HepG2 | T2100 | 3:1 | 55–70 | >85 |
| A549 | T2100 | 3:1 | 60–75 | >90 |
| NIH/3T3 | T2100 | 2:1 | 65–80 | >95 |
| HUVEC (primary) | T2200 | 3:1 | 55–70 | >85 |
| MSC (primary) | T2200 | 4:1 | 35–50 | >75 |
| Primary neurons | T2200 | 4:1 | 20–35 | >70 |
| Jurkat (suspension) | T2100 | 2:1 | 50–65 | >80 |
| RAW 264.7 | T2100 | 3:1 | 30–45 | >75 |

## 6. Optimization Guide

### 6.1 Parameter Matrix

| Parameter | Recommended Range | Strategy |
|---|---|---|
| DNA amount (24-well) | 0.25–2 μg | Titrate in 2-fold increments; measure both efficiency and viability |
| Reagent:DNA ratio | 1:1 to 5:1 (v/w) | Test 1:1, 2:1, 3:1, 4:1; higher ratios may increase efficiency but reduce viability |
| Cell density | 50–90% confluency | Lower density → higher efficiency, lower viability; higher density → lower efficiency, higher viability |
| DNA quality | A₂₆₀/A₂₈₀ 1.8–2.0 | Endotoxin-free maxiprep recommended; avoid RNA contamination |
| Serum during transfection | 0–10% | Complex formation in serum-free medium; add to cells with or without serum |

### 6.2 Critical Factors

| Factor | Impact | Recommendation |
|---|---|---|
| Antibiotics | Cationic lipids increase membrane permeability → antibiotics enter cells → cytotoxicity | Omit penicillin/streptomycin during transfection |
| Passage number (primary cells) | High passage → reduced efficiency | Use passages 2–6 for primary cells |
| DNA purity | Impurities (phenol, ethanol, endotoxin) → cytotoxicity | Endotoxin-free maxiprep; A₂₆₀/A₂₈₀ 1.8–2.0 |
| siRNA concentration | High concentration → off-target effects | Use 10–50 nM for well-characterized siRNA; validate with 2 independent sequences |
| Medium change timing | Prolonged complex incubation → toxicity | For sensitive cells: change medium after 4–6 h |

## 7. Troubleshooting

| Issue | Possible Cause | Solution |
|---|---|---|
| Low efficiency, acceptable viability | Reagent:DNA ratio too low; cell confluency too high | Increase ratio; reduce seeding density |
| Low efficiency, low viability | Reagent:DNA ratio too high; complexes toxic | Reduce ratio; change medium after 4 h; use fewer complexes |
| Cell death after transfection | Antibiotic present; DNA impure; cells too sparse | Omit antibiotics; purify DNA; increase cell density |
| High cell death in primary cells | T2100 too harsh for sensitive cells | Switch to T2200; reduce complex volume |
| No GFP expression | Plasmid quality issues; promoter not active in cell type | Verify plasmid map; check cell-specific promoter activity; include positive control (CMV-GFP) |
| siRNA no knockdown | Low delivery; target sequence weak | Increase siRNA to 50 nM; test 2–3 independent siRNAs; qRT-PCR confirmation |

## 8. Cross-References

- [▶ Related Protocol: Cell Culture Protocol](../protocols/cell-culture-protocol.md)
- [▶ Related Protocol: Competent Cell Transformation](../protocols/competent-cell-transformation.md)
- [▶ See also: Cell Proliferation Assay Kits](cell-proliferation.md)

*For product procurement: [solarbio.store](https://solarbio.store)*
